Zhao Y, et al. - Researchers intended to test the validity of IP-10 and RANTES plasma levels for use in diagnosis and monitoring of pulmonary tuberculosis (PTB). In clinically suspected PTB patients including a training set and two independent test sets A and B, significantly higher plasma levels of IP-10 and RANTES were found in PTB patients vs healthy controls. With an AUC of 1.0 in training set, the combination of IP-10 and RANTES displayed the best performance relative to other combinations. A positive correlation of IP-10 levels with CRP and ESR was observed in PTB patients. Therapy over the period of 6 months resulted in a significant decrease in both IP-10 and RANTES levels. Overall, the combination of IP-10 and RANTES could be potentially used as diagnostic and monitoring biomarker in PTB management.